ARCHIVES

FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart

This article is from The Cancer Letter archive.

Vol. 36 No. 44 | December 3, 2010

Download PDF Visit The Full Archive

Related Articles

Study Finds No Benefit From CT In Lung Cancer; Advocacy Group Alleges “Delaying Tactic.”

March 9, 2007

NCI Still Supporting Construction Grants Despite Big Cuts

February 20, 1981

Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication

November 25, 2011

Conference Split Difference, NCI Gets $1.075 Billion

October 21, 1983

ACS names new officers.

December 5, 2003

NCI-Funded Modelers Accurately Predicted Outcome Of Lung Cancer Screening Trial

November 26, 2010